 Michael Arnold
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 7 | 2023 | 55 | 2.150 |
Why?
| | Sarcoma | 6 | 2024 | 138 | 1.520 |
Why?
| | Cancer Survivors | 13 | 2023 | 205 | 1.510 |
Why?
| | Wilms Tumor | 4 | 2022 | 69 | 1.490 |
Why?
| | Desmoplastic Small Round Cell Tumor | 3 | 2022 | 3 | 1.460 |
Why?
| | Sarcoma, Ewing | 4 | 2022 | 65 | 1.450 |
Why?
| | Kidney Neoplasms | 5 | 2022 | 334 | 1.280 |
Why?
| | Neoplasms, Second Primary | 8 | 2023 | 94 | 1.240 |
Why?
| | Biomarkers, Tumor | 7 | 2023 | 1054 | 1.220 |
Why?
| | Bone Neoplasms | 4 | 2024 | 194 | 1.160 |
Why?
| | Immunohistochemistry | 6 | 2016 | 1635 | 1.020 |
Why?
| | Oncogene Proteins, Fusion | 7 | 2022 | 179 | 0.980 |
Why?
| | Thyroid Neoplasms | 5 | 2021 | 263 | 0.960 |
Why?
| | Rhabdomyosarcoma, Alveolar | 3 | 2021 | 10 | 0.860 |
Why?
| | Hirschsprung Disease | 5 | 2023 | 90 | 0.800 |
Why?
| | Gene Fusion | 3 | 2020 | 18 | 0.790 |
Why?
| | Gastritis | 3 | 2024 | 84 | 0.780 |
Why?
| | Myogenic Regulatory Factors | 8 | 2009 | 49 | 0.740 |
Why?
| | Child | 44 | 2024 | 18362 | 0.720 |
Why?
| | Gallbladder Diseases | 1 | 2019 | 6 | 0.660 |
Why?
| | Inclusion Bodies | 1 | 2019 | 24 | 0.660 |
Why?
| | Pyridines | 3 | 2022 | 425 | 0.650 |
Why?
| | Azabicyclo Compounds | 1 | 2017 | 5 | 0.600 |
Why?
| | Niacin | 1 | 2017 | 18 | 0.590 |
Why?
| | Neoplasms, Radiation-Induced | 5 | 2021 | 66 | 0.590 |
Why?
| | Sarcoma, Synovial | 2 | 2018 | 11 | 0.580 |
Why?
| | Helicobacter | 1 | 2016 | 5 | 0.560 |
Why?
| | Helicobacter Infections | 1 | 2016 | 25 | 0.550 |
Why?
| | Stomach | 1 | 2016 | 101 | 0.540 |
Why?
| | Child, Preschool | 23 | 2024 | 9083 | 0.530 |
Why?
| | Carbodiimides | 2 | 2006 | 4 | 0.530 |
Why?
| | Imines | 2 | 2006 | 7 | 0.530 |
Why?
| | Breast Neoplasms | 6 | 2023 | 1870 | 0.530 |
Why?
| | Alkaloids | 2 | 2006 | 22 | 0.530 |
Why?
| | Infant | 19 | 2023 | 7936 | 0.520 |
Why?
| | Biopsy | 9 | 2019 | 1045 | 0.520 |
Why?
| | Rhabdomyosarcoma, Embryonal | 3 | 2022 | 16 | 0.520 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 92 | 0.520 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2013 | 100 | 0.510 |
Why?
| | Adolescent | 30 | 2024 | 17826 | 0.500 |
Why?
| | Neoplasms | 8 | 2022 | 2106 | 0.490 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1477 | 0.490 |
Why?
| | Humans | 77 | 2024 | 114925 | 0.490 |
Why?
| | Frozen Sections | 1 | 2015 | 24 | 0.490 |
Why?
| | Colestipol | 1 | 2014 | 1 | 0.490 |
Why?
| | Ion Exchange Resins | 1 | 2014 | 5 | 0.490 |
Why?
| | Thyroid Diseases | 1 | 2015 | 30 | 0.490 |
Why?
| | Allylamine | 1 | 2014 | 7 | 0.490 |
Why?
| | Pathology, Surgical | 1 | 2014 | 7 | 0.490 |
Why?
| | Intestines | 2 | 2015 | 326 | 0.490 |
Why?
| | Biopsy, Fine-Needle | 1 | 2015 | 64 | 0.480 |
Why?
| | Transcription Factors | 6 | 2017 | 1530 | 0.480 |
Why?
| | Thyroid Gland | 1 | 2015 | 84 | 0.470 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1400 | 0.460 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.460 |
Why?
| | S100 Proteins | 1 | 2014 | 38 | 0.460 |
Why?
| | Specimen Handling | 1 | 2014 | 156 | 0.440 |
Why?
| | Cerebral Ventricle Neoplasms | 1 | 2013 | 4 | 0.440 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2013 | 17 | 0.430 |
Why?
| | Anticholesteremic Agents | 1 | 2014 | 128 | 0.420 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2014 | 224 | 0.420 |
Why?
| | DNA-Binding Proteins | 4 | 2013 | 1317 | 0.420 |
Why?
| | Rectum | 4 | 2023 | 153 | 0.410 |
Why?
| | Female | 49 | 2024 | 59571 | 0.400 |
Why?
| | Young Adult | 20 | 2023 | 10476 | 0.400 |
Why?
| | DNA | 2 | 2017 | 1351 | 0.380 |
Why?
| | Skin Neoplasms | 2 | 2019 | 762 | 0.370 |
Why?
| | Societies, Medical | 1 | 2014 | 677 | 0.370 |
Why?
| | Guideline Adherence | 1 | 2014 | 490 | 0.360 |
Why?
| | Male | 40 | 2024 | 55655 | 0.360 |
Why?
| | Soft Tissue Neoplasms | 2 | 2024 | 90 | 0.360 |
Why?
| | Guanidines | 2 | 2006 | 33 | 0.340 |
Why?
| | Predictive Value of Tests | 6 | 2017 | 1801 | 0.320 |
Why?
| | WT1 Proteins | 2 | 2022 | 12 | 0.320 |
Why?
| | Paired Box Transcription Factors | 3 | 2020 | 37 | 0.320 |
Why?
| | Risk Assessment | 8 | 2021 | 2975 | 0.320 |
Why?
| | Adult | 27 | 2023 | 30604 | 0.310 |
Why?
| | Retrospective Studies | 15 | 2024 | 12543 | 0.310 |
Why?
| | Risk Factors | 14 | 2023 | 8637 | 0.300 |
Why?
| | Gram-Negative Bacteria | 2 | 2018 | 66 | 0.290 |
Why?
| | Diagnosis, Differential | 5 | 2020 | 1355 | 0.290 |
Why?
| | Bone Development | 1 | 2007 | 47 | 0.280 |
Why?
| | Pediatrics | 1 | 2014 | 984 | 0.280 |
Why?
| | Colon | 3 | 2019 | 233 | 0.280 |
Why?
| | Pyrimidines | 2 | 2006 | 378 | 0.270 |
Why?
| | Intestinal Mucosa | 4 | 2019 | 530 | 0.260 |
Why?
| | Bone and Bones | 2 | 2018 | 278 | 0.260 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 1897 | 0.260 |
Why?
| | Vinyl Compounds | 1 | 2005 | 5 | 0.250 |
Why?
| | Guanidine | 1 | 2005 | 18 | 0.250 |
Why?
| | Cartilage | 1 | 2007 | 182 | 0.250 |
Why?
| | Survivors | 2 | 2019 | 411 | 0.250 |
Why?
| | Radiotherapy | 3 | 2021 | 176 | 0.240 |
Why?
| | Infant, Newborn | 10 | 2022 | 5035 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 4 | 2020 | 2102 | 0.240 |
Why?
| | Carcinoma, Renal Cell | 2 | 2020 | 173 | 0.240 |
Why?
| | Chondrocytes | 1 | 2007 | 199 | 0.240 |
Why?
| | Eosinophilia | 2 | 2024 | 186 | 0.240 |
Why?
| | Mutation | 5 | 2021 | 3353 | 0.240 |
Why?
| | Pathology | 1 | 2024 | 20 | 0.230 |
Why?
| | Duodenitis | 1 | 2024 | 7 | 0.230 |
Why?
| | Polyketides | 1 | 2023 | 3 | 0.220 |
Why?
| | Education, Distance | 1 | 2024 | 38 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1361 | 0.220 |
Why?
| | Dysautonomia, Familial | 1 | 2023 | 2 | 0.220 |
Why?
| | Disease-Free Survival | 4 | 2020 | 623 | 0.220 |
Why?
| | Microbial Sensitivity Tests | 3 | 2022 | 301 | 0.220 |
Why?
| | Orbital Neoplasms | 1 | 2023 | 21 | 0.210 |
Why?
| | SMARCB1 Protein | 2 | 2013 | 17 | 0.210 |
Why?
| | Prognosis | 7 | 2023 | 3344 | 0.210 |
Why?
| | Eyelids | 1 | 2023 | 29 | 0.210 |
Why?
| | Retinal Degeneration | 1 | 2023 | 30 | 0.210 |
Why?
| | Mice | 17 | 2023 | 14935 | 0.210 |
Why?
| | Enterocolitis | 1 | 2023 | 33 | 0.210 |
Why?
| | Telomere Homeostasis | 2 | 2020 | 24 | 0.200 |
Why?
| | Bone Marrow | 1 | 2023 | 245 | 0.200 |
Why?
| | Ribonucleotide Reductases | 1 | 2022 | 21 | 0.200 |
Why?
| | Norwood Procedures | 1 | 2022 | 22 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 706 | 0.200 |
Why?
| | Age Factors | 4 | 2019 | 2891 | 0.200 |
Why?
| | Incidence | 7 | 2022 | 2316 | 0.200 |
Why?
| | Radiation Dosage | 2 | 2019 | 136 | 0.200 |
Why?
| | Muscle Proteins | 3 | 2017 | 210 | 0.200 |
Why?
| | Telomere Shortening | 1 | 2021 | 17 | 0.200 |
Why?
| | Vulvar Neoplasms | 1 | 2021 | 10 | 0.200 |
Why?
| | MEF2 Transcription Factors | 8 | 2009 | 55 | 0.200 |
Why?
| | Appendix | 1 | 2021 | 26 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 91 | 0.190 |
Why?
| | Alphapapillomavirus | 1 | 2021 | 36 | 0.190 |
Why?
| | Histone Deacetylases | 3 | 2007 | 196 | 0.190 |
Why?
| | MyoD Protein | 2 | 2021 | 27 | 0.190 |
Why?
| | Middle Aged | 15 | 2021 | 26801 | 0.190 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2022 | 110 | 0.190 |
Why?
| | Gonorrhea | 1 | 2022 | 54 | 0.190 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 20 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 3 | 2023 | 817 | 0.190 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 155 | 0.180 |
Why?
| | Forkhead Box Protein O1 | 1 | 2020 | 15 | 0.180 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 222 | 0.180 |
Why?
| | Schwann Cells | 1 | 2020 | 27 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 863 | 0.180 |
Why?
| | Colitis | 2 | 2021 | 226 | 0.180 |
Why?
| | Chromosome Breakpoints | 1 | 2020 | 6 | 0.180 |
Why?
| | Rhabdomyoma | 1 | 2020 | 9 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2018 | 165 | 0.180 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2020 | 22 | 0.180 |
Why?
| | Nanoparticles | 2 | 2015 | 313 | 0.180 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 399 | 0.170 |
Why?
| | Colitis, Ischemic | 1 | 2019 | 6 | 0.170 |
Why?
| | Reproducibility of Results | 3 | 2021 | 2769 | 0.170 |
Why?
| | Phenotype | 5 | 2015 | 2817 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2021 | 1893 | 0.170 |
Why?
| | Diagnostic Errors | 3 | 2017 | 151 | 0.170 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2020 | 38 | 0.170 |
Why?
| | Structure-Activity Relationship | 2 | 2018 | 503 | 0.170 |
Why?
| | Heart Neoplasms | 1 | 2020 | 49 | 0.170 |
Why?
| | Neurogenesis | 1 | 2020 | 102 | 0.170 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 14 | 0.170 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 105 | 0.170 |
Why?
| | Neural Stem Cells | 1 | 2020 | 115 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2020 | 447 | 0.170 |
Why?
| | Carcinoid Tumor | 1 | 2019 | 25 | 0.170 |
Why?
| | Gallbladder | 1 | 2019 | 14 | 0.170 |
Why?
| | Neurofibromatosis 1 | 1 | 2019 | 36 | 0.160 |
Why?
| | Vagina | 1 | 2021 | 146 | 0.160 |
Why?
| | Research Report | 1 | 2019 | 75 | 0.160 |
Why?
| | Prospective Studies | 5 | 2021 | 6218 | 0.160 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 62 | 0.160 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2019 | 19 | 0.160 |
Why?
| | Cholecystectomy | 1 | 2019 | 45 | 0.160 |
Why?
| | Enteric Nervous System | 1 | 2019 | 26 | 0.160 |
Why?
| | Telomere-Binding Proteins | 1 | 2020 | 88 | 0.160 |
Why?
| | Gene Rearrangement | 2 | 2022 | 138 | 0.160 |
Why?
| | Glucose Transporter Type 1 | 1 | 2018 | 42 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2019 | 128 | 0.160 |
Why?
| | Anal Canal | 1 | 2019 | 83 | 0.160 |
Why?
| | Ohio | 2 | 2017 | 135 | 0.150 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 90 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1148 | 0.150 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2018 | 23 | 0.150 |
Why?
| | Age of Onset | 1 | 2019 | 448 | 0.150 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2018 | 44 | 0.150 |
Why?
| | Glioma | 1 | 2021 | 296 | 0.150 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 390 | 0.150 |
Why?
| | Epithelium | 1 | 2019 | 298 | 0.150 |
Why?
| | Escherichia coli | 2 | 2022 | 722 | 0.150 |
Why?
| | Carcinoma, Basal Cell | 1 | 2019 | 68 | 0.150 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2018 | 63 | 0.150 |
Why?
| | Curriculum | 1 | 2024 | 845 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2022 | 296 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.150 |
Why?
| | Animals | 17 | 2023 | 31837 | 0.150 |
Why?
| | Half-Life | 1 | 2017 | 141 | 0.150 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 37 | 0.150 |
Why?
| | Interleukin-8 | 1 | 2018 | 238 | 0.140 |
Why?
| | Povidone | 1 | 2017 | 5 | 0.140 |
Why?
| | Immunocompromised Host | 1 | 2019 | 196 | 0.140 |
Why?
| | Nephroma, Mesoblastic | 1 | 2017 | 3 | 0.140 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 190 | 0.140 |
Why?
| | Drug Discovery | 1 | 2018 | 124 | 0.140 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2017 | 10 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2017 | 32 | 0.140 |
Why?
| | Cohort Studies | 6 | 2023 | 4903 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.140 |
Why?
| | Excipients | 1 | 2017 | 49 | 0.140 |
Why?
| | Pathology, Clinical | 1 | 2017 | 32 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 287 | 0.140 |
Why?
| | Candidiasis | 1 | 2017 | 52 | 0.140 |
Why?
| | Cellulose | 1 | 2017 | 57 | 0.140 |
Why?
| | Esophagitis | 1 | 2017 | 65 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2022 | 667 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2020 | 509 | 0.130 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 5 | 0.130 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.130 |
Why?
| | Enterocolitis, Neutropenic | 1 | 2015 | 5 | 0.130 |
Why?
| | Survival Rate | 4 | 2023 | 1644 | 0.130 |
Why?
| | Stereoisomerism | 2 | 2006 | 91 | 0.130 |
Why?
| | beta 2-Microglobulin | 1 | 2015 | 45 | 0.130 |
Why?
| | Virus Internalization | 1 | 2015 | 40 | 0.130 |
Why?
| | Cardiac Surgical Procedures | 1 | 2020 | 414 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 934 | 0.130 |
Why?
| | Immunotherapy | 2 | 2018 | 475 | 0.130 |
Why?
| | Receptors, Virus | 1 | 2015 | 75 | 0.130 |
Why?
| | Sarcoma, Experimental | 1 | 2015 | 5 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 929 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 666 | 0.120 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 12 | 0.120 |
Why?
| | Granuloma, Foreign-Body | 1 | 2015 | 10 | 0.120 |
Why?
| | Information Dissemination | 1 | 2017 | 188 | 0.120 |
Why?
| | Colesevelam Hydrochloride | 1 | 2014 | 7 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2014 | 7 | 0.120 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 169 | 0.120 |
Why?
| | Thyroidectomy | 1 | 2015 | 52 | 0.120 |
Why?
| | Herpesvirus 1, Human | 1 | 2015 | 76 | 0.120 |
Why?
| | Neuroblastoma | 1 | 2015 | 132 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2016 | 314 | 0.120 |
Why?
| | Desmin | 1 | 2014 | 31 | 0.120 |
Why?
| | Albumins | 1 | 2015 | 89 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2018 | 676 | 0.120 |
Why?
| | Social Media | 1 | 2017 | 133 | 0.120 |
Why?
| | Quality Control | 1 | 2014 | 144 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 174 | 0.120 |
Why?
| | Muscle, Skeletal | 4 | 2007 | 1472 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 60 | 0.120 |
Why?
| | Cerebral Ventricles | 1 | 2014 | 47 | 0.120 |
Why?
| | Tubulin | 1 | 2015 | 123 | 0.110 |
Why?
| | Paclitaxel | 1 | 2015 | 190 | 0.110 |
Why?
| | Keratins | 1 | 2014 | 176 | 0.110 |
Why?
| | MicroRNAs | 1 | 2020 | 601 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 546 | 0.110 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2014 | 60 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2022 | 9105 | 0.110 |
Why?
| | Vascular Malformations | 1 | 2014 | 47 | 0.110 |
Why?
| | Microscopy | 1 | 2014 | 125 | 0.110 |
Why?
| | Cerebral Hemorrhage | 1 | 2014 | 96 | 0.110 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.110 |
Why?
| | Ileal Neoplasms | 1 | 2013 | 4 | 0.110 |
Why?
| | Glucose-6-Phosphatase | 1 | 2013 | 31 | 0.110 |
Why?
| | Hypertrophy | 2 | 2018 | 111 | 0.110 |
Why?
| | Food | 1 | 2015 | 160 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4427 | 0.110 |
Why?
| | Repressor Proteins | 2 | 2006 | 368 | 0.110 |
Why?
| | Cell Line, Tumor | 5 | 2019 | 2725 | 0.110 |
Why?
| | United States | 7 | 2019 | 12209 | 0.110 |
Why?
| | Lateral Ventricles | 1 | 2013 | 24 | 0.110 |
Why?
| | Calcium Phosphates | 1 | 2013 | 24 | 0.110 |
Why?
| | Human Growth Hormone | 1 | 2013 | 38 | 0.110 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 183 | 0.110 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 135 | 0.100 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 52 | 0.100 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 45 | 0.100 |
Why?
| | Neutropenia | 1 | 2013 | 125 | 0.100 |
Why?
| | COS Cells | 3 | 2007 | 175 | 0.100 |
Why?
| | Sepsis | 1 | 2018 | 508 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1080 | 0.100 |
Why?
| | Endocytosis | 1 | 2013 | 151 | 0.100 |
Why?
| | Enteritis | 2 | 2024 | 82 | 0.100 |
Why?
| | Patient Selection | 1 | 2015 | 642 | 0.100 |
Why?
| | Colonic Polyps | 1 | 2013 | 68 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2019 | 987 | 0.100 |
Why?
| | Rhabdoid Tumor | 1 | 2012 | 80 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2014 | 737 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2013 | 154 | 0.100 |
Why?
| | Spinal Cord | 1 | 2014 | 348 | 0.100 |
Why?
| | Adenoma | 1 | 2013 | 189 | 0.090 |
Why?
| | Recurrence | 3 | 2024 | 937 | 0.090 |
Why?
| | Colonoscopy | 1 | 2013 | 205 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 543 | 0.090 |
Why?
| | Constipation | 2 | 2023 | 76 | 0.090 |
Why?
| | Sarcomeres | 2 | 2007 | 90 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1126 | 0.090 |
Why?
| | SEER Program | 2 | 2021 | 196 | 0.080 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2382 | 0.080 |
Why?
| | Aged | 6 | 2019 | 19120 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2007 | 185 | 0.080 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2009 | 62 | 0.080 |
Why?
| | Coccidioidomycosis | 1 | 2008 | 7 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1700 | 0.080 |
Why?
| | Cell Proliferation | 3 | 2018 | 2199 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2013 | 560 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 47 | 0.080 |
Why?
| | Risk | 2 | 2021 | 815 | 0.070 |
Why?
| | Doxorubicin | 2 | 2023 | 286 | 0.070 |
Why?
| | Waste Disposal, Fluid | 1 | 2008 | 45 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2007 | 799 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3008 | 0.070 |
Why?
| | Canada | 2 | 2019 | 322 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2007 | 1953 | 0.070 |
Why?
| | Dwarfism | 1 | 2007 | 16 | 0.070 |
Why?
| | Pressure | 1 | 2008 | 218 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 128 | 0.070 |
Why?
| | Gastroschisis | 1 | 2006 | 15 | 0.070 |
Why?
| | Colectomy | 2 | 2019 | 86 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 434 | 0.070 |
Why?
| | Actinin | 1 | 2006 | 13 | 0.070 |
Why?
| | Cell Differentiation | 3 | 2008 | 1699 | 0.060 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2005 | 6 | 0.060 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 334 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2222 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2007 | 173 | 0.060 |
Why?
| | Alkylation | 1 | 2005 | 18 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1133 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1180 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2017 | 6363 | 0.060 |
Why?
| | Osteogenesis | 1 | 2007 | 183 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2007 | 2791 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 744 | 0.060 |
Why?
| | Base Sequence | 4 | 2013 | 2118 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 6125 | 0.060 |
Why?
| | Molecular Medicine | 1 | 2024 | 2 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2006 | 236 | 0.060 |
Why?
| | Daunorubicin | 1 | 2023 | 24 | 0.060 |
Why?
| | Podophyllotoxin | 1 | 2023 | 7 | 0.060 |
Why?
| | Anthracyclines | 1 | 2023 | 41 | 0.060 |
Why?
| | Public Opinion | 1 | 2024 | 59 | 0.050 |
Why?
| | Kinetin | 1 | 2023 | 1 | 0.050 |
Why?
| | Gait Ataxia | 1 | 2023 | 5 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1749 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 316 | 0.050 |
Why?
| | Breast | 1 | 2023 | 141 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 210 | 0.050 |
Why?
| | Placenta | 1 | 2008 | 626 | 0.050 |
Why?
| | Deoxyadenine Nucleotides | 1 | 2022 | 13 | 0.050 |
Why?
| | Neisseria gonorrhoeae | 1 | 2022 | 20 | 0.050 |
Why?
| | Educational Measurement | 1 | 2024 | 257 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2022 | 82 | 0.050 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2024 | 204 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 696 | 0.050 |
Why?
| | Mice, SCID | 2 | 2015 | 320 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 45 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2023 | 227 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2021 | 44 | 0.050 |
Why?
| | Colon, Sigmoid | 1 | 2021 | 15 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2021 | 102 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 180 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 79 | 0.050 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 44 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 243 | 0.050 |
Why?
| | Myocardium | 1 | 2006 | 911 | 0.050 |
Why?
| | Administration, Oral | 1 | 2023 | 731 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 159 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2324 | 0.040 |
Why?
| | Cloaca | 1 | 2021 | 48 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 104 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2021 | 182 | 0.040 |
Why?
| | Mice, Knockout | 4 | 2007 | 2586 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2021 | 209 | 0.040 |
Why?
| | Transcription Initiation Site | 1 | 2020 | 40 | 0.040 |
Why?
| | Genomic Instability | 1 | 2020 | 38 | 0.040 |
Why?
| | Genes, ras | 1 | 2020 | 91 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 272 | 0.040 |
Why?
| | Eosinophils | 1 | 2022 | 280 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2023 | 464 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 317 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 1 | 2019 | 33 | 0.040 |
Why?
| | Internet | 1 | 2024 | 599 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2019 | 128 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 85 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2019 | 245 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 262 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2019 | 69 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 56 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2022 | 1152 | 0.040 |
Why?
| | Introns | 1 | 2020 | 227 | 0.040 |
Why?
| | Anorectal Malformations | 1 | 2020 | 103 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2013 | 312 | 0.040 |
Why?
| | North America | 1 | 2019 | 257 | 0.040 |
Why?
| | Receptors, Interleukin-8A | 1 | 2018 | 5 | 0.040 |
Why?
| | Cytokine Receptor gp130 | 1 | 2018 | 10 | 0.040 |
Why?
| | Diarrhea | 1 | 2019 | 173 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2019 | 217 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2019 | 136 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 481 | 0.040 |
Why?
| | Hydrazines | 1 | 2018 | 28 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 245 | 0.040 |
Why?
| | Appendicitis | 1 | 2019 | 109 | 0.040 |
Why?
| | Quinoxalines | 1 | 2018 | 60 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 149 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2018 | 67 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 184 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2018 | 155 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 114 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 263 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 277 | 0.040 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 272 | 0.040 |
Why?
| | DNA Methylation | 1 | 2021 | 496 | 0.040 |
Why?
| | Computer Simulation | 1 | 2021 | 880 | 0.040 |
Why?
| | Leukocytes | 1 | 2018 | 277 | 0.040 |
Why?
| | Up-Regulation | 1 | 2020 | 812 | 0.040 |
Why?
| | HLA Antigens | 1 | 2018 | 224 | 0.040 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 468 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 563 | 0.030 |
Why?
| | Molecular Structure | 1 | 2018 | 438 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 134 | 0.030 |
Why?
| | Recovery of Function | 1 | 2020 | 572 | 0.030 |
Why?
| | Medical Informatics | 1 | 2017 | 92 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 728 | 0.030 |
Why?
| | Embryo, Mammalian | 2 | 2007 | 214 | 0.030 |
Why?
| | Biomarkers | 2 | 2022 | 3418 | 0.030 |
Why?
| | Palliative Care | 1 | 2022 | 639 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 50 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 604 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 149 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2326 | 0.030 |
Why?
| | Osteonectin | 1 | 2015 | 2 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1856 | 0.030 |
Why?
| | Protein Conformation | 1 | 2018 | 811 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 271 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2015 | 20 | 0.030 |
Why?
| | Signal Transduction | 3 | 2019 | 4524 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 530 | 0.030 |
Why?
| | Sulfonamides | 1 | 2018 | 445 | 0.030 |
Why?
| | Genetic Variation | 1 | 2020 | 876 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 195 | 0.030 |
Why?
| | Skin | 1 | 2019 | 659 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2015 | 285 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 2014 | 39 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 635 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 71 | 0.030 |
Why?
| | Dwarfism, Pituitary | 1 | 2013 | 3 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2013 | 6 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 285 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 855 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2392 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1379 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 136 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1197 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 164 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 3549 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2013 | 410 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2014 | 211 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2013 | 3897 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2023 | 2132 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 372 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1087 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 305 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 1988 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 514 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2485 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2640 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 642 | 0.020 |
Why?
| | Protein Binding | 2 | 2007 | 1897 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1523 | 0.020 |
Why?
| | Heart Arrest | 1 | 2014 | 289 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2013 | 536 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4634 | 0.020 |
Why?
| | Leukemia Virus, Murine | 1 | 2009 | 16 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 89 | 0.020 |
Why?
| | Interferon Regulatory Factors | 1 | 2009 | 29 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2009 | 49 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2009 | 113 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 241 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2009 | 4718 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 78 | 0.020 |
Why?
| | Water Movements | 1 | 2008 | 22 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 445 | 0.020 |
Why?
| | Sewage | 1 | 2008 | 27 | 0.020 |
Why?
| | Leupeptins | 1 | 2007 | 10 | 0.020 |
Why?
| | Connectin | 1 | 2007 | 30 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2558 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 561 | 0.020 |
Why?
| | Ubiquitin | 1 | 2007 | 57 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 277 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 134 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2008 | 172 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2008 | 267 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2006 | 109 | 0.020 |
Why?
| | Isoenzymes | 1 | 2007 | 285 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2006 | 68 | 0.020 |
Why?
| | Protein Methyltransferases | 1 | 2006 | 2 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 385 | 0.020 |
Why?
| | Lung | 1 | 2018 | 3593 | 0.020 |
Why?
| | Gene Deletion | 1 | 2007 | 356 | 0.020 |
Why?
| | Veins | 1 | 2006 | 56 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2007 | 777 | 0.020 |
Why?
| | Monocytes | 1 | 2008 | 504 | 0.020 |
Why?
| | Cell Movement | 1 | 2009 | 867 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 596 | 0.020 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2006 | 95 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 225 | 0.020 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 287 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2005 | 152 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 927 | 0.010 |
Why?
| | Arteries | 1 | 2006 | 247 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 797 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 386 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3053 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1422 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2005 | 1317 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 5525 | 0.010 |
Why?
|
|
Arnold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|